Results 111 to 120 of about 205,939 (352)

MTOR cross-talk in cancer and potential for combination therapy [PDF]

, 2018
The mammalian Target of Rapamycin (mTOR) pathway plays an essential role in sensing and integrating a variety of exogenous cues to regulate cellular growth and metabolism, in both physiological and pathological conditions.
Bazzichetto, C., Bria, E., Ciuffreda, L., Cognetti, F., Conciatori, F., Falcone, I., Milella, M, Pilotto, S.   +7 more
core   +3 more sources

Investigation of Clinical, Laboratory, Imaging Findings and Histopathological Features of Patients wıth Gastric Neuroendocrine Cell Hyperplasia

The Turkish Journal of Gastroenterology
Background/Aims: Neuroendocrine cell hyperplasia is a non-neoplastic proliferation of enterochromaffin-like cells and is considered a premalignant lesion because of their potential to progress to neuroendocrine tumor.
Burcu Çoban , Göksel Bengi, Gözde Derviş Hakim, Şadiye Mehtat Ünlü, Dudu Solakoğlu Kahraman, Funda Barlık, Gamze Çapa Kaya, Müjde Soytürk   +7 more
doaj   +1 more source

Spermidine Reproduces the Anti‐Inflammatory Effects of Intermittent Fasting and Prevents Urate and Calcium Pyrophosphate Crystal‐Induced Inflammation

Arthritis &Rheumatology, EarlyView.
Objective Gout caused by the formation of monosodium urate (MSU) crystals and calcium pyrophosphate (CPP) deposition disease are two major types of microcrystalline pathologies in adults. They are responsible for recurrent flares that rely on interleukin (IL) 1β via activation of the NLRP3 inflammasome.
Chinh Nghia Pham, Florence Castelli, Flora Finet, Charles Leroy, Céline Chollet, Twinu W. Chirayath, Subhalaxmi Moitra, Mylène Zarka, Agnès Ostertag, François Brial, Christèle Combes, Augustin Latourte, Thomas Bardin, François Fenaille, Pascal Richette, Hang Korng Ea   +15 more
wiley   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. [PDF]

, 2014
PurposeWe hypothesized that bortezomib, an agent that suppresses HIF-1α transcriptional activity, when combined with bevacizumab, would obviate the HIF-1α resistance pathway.
Amin, Hesham M, Angelo, Laura S, Falchook, Gerald S, Hess, Kenneth, Hong, David, Howard, Adrienne N, Huang, Mei, Jackson, Edward F, Janku, Filip, Kurzrock, Razelle, Lawhorn, Kristie N, Naing, Aung, Ng, Chaan S, Parkhurst, Kristin L, Tannir, Nizar M, Vishwamitra, Deeksha, Wheler, Jennifer J   +16 more
core   +2 more sources

Metastatic jejunal neuroendocrine tumor to the breast: Case report and literature review [PDF]

, 2022
Gonzalo Fernández-Christlieb, Ana Rivera García-Granados, Daniel Kajomovitz-Bialostozky   +2 more
openalex   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes. [PDF]

, 2013
BACKGROUND: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are heterogeneous with respect to biological behaviour and prognosis. As angiogenesis is a renowned pathogenic hallmark as well as a therapeutic target, we aimed to investigate the ...
A Couvelard, A Giatromanolaki, A Rinke, AM Marion-Audibert, AT Dimou, B Terris, D Hanahan, D J Pinato, D O’Toole, DC Metz, DJ Pinato, DJ Pinato, E Raymond, EP Hui, F Panzuto, G Kloppel, HS Kim, I Albrecht, IM Modlin, J LeCouter, J Strosberg, J Zhang, JC Yao, JT Chi, JY Scoazec, K Hirabayashi, K Meeran, K Villaume, M Dal Monte, M Perigny, M Ruscica, MA Maynard, N Martin, N Ngo, P Kuiper, R Dina, R Katoh, R Mentlein, R Ramachandran, R Sharma, S Ezziddin, S T K Toussi, T M Tan, VD Corleto, Y Arvidsson, Y Seo, Y Takahashi, YC Patel   +47 more
core   +2 more sources

A Phase II Trial of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors [PDF]

, 2019
Daniel M. Halperin, J. Jack Lee, Chaan S. Ng, Jonathan Strosberg, Jeannelyn S. Estrella, Cecile G. Dagohoy, Arvind Dasari, James C. Yao   +7 more
openalex   +1 more source

Ovarian Endometrioid Adenocarcinomas With Infiltrative “Adenofibroma-like” Morphology and Aberrant ß-catenin Expression: Tumors That Coexpress CDX2 and LEF1 With Frequent Neuroendocrine Marker Expression, Diminished/Lost PAX8 and Possible Association With Endometrioid Type II Stem Cell Outgrowths in the Fallopian Tube [PDF]

, 2023
Jin Xu, Stephanie M. McGregor, Kay J. Park, Paul Weisman   +3 more
openalex   +1 more source